Jefferies Starts Coverage on Definium Therapeutics with Buy Rating and $30 Target

Jefferies initiated coverage on Definium Therapeutics with a Buy rating, citing strong Phase IIb results for its anxiety drug DT120 and high confidence ahead of Phase III trials.